[Eldecalcitol (ED-71)].

Abstract

ED-71 is a new vitamin D receptor ligand, bearing a hydroxypropoxy substituent at the 2β-position of 1α, 25 (OH) (2)D(3). In ovariectomized rats, ED-71 increased vertebral bone mass and bone strength by inhibiting bone resorption and maintaining bone formation. In randomized, placebo-controlled, double-blinded clinical trial for osteoporotic subjects, ED-71 increased lumber vertebral and hip bone mineral density independently vitamin D status. Furthermore, ED-71 may have a better osteoprotective effect than alfacalcidol and suggest that ED-71 may serve as a new generation of active vitamin D with anti-fracture efficacy in osteiporotic subjects.

• Authors: Itsuro Endo, Toshio Matsumoto
• Journal: Clinical calcium (Clin Calcium) Vol. 21 Issue 1 Pg. 53-8 (Jan 2011) ISSN: 0917-5857 [Print] Japan
• PMID: 21187594 (Publication Type: Journal Article, Review)

Chemical References

• Vitamin D
• eldecalcitol

Topics

• Animals
• Bone Density (drug effects)
• Bone Resorption (drug therapy)
• Dose-Response Relationship, Drug
• Female
• Fractures, Bone (etiology, prevention & control)
• Humans
• Lumbar Vertebrae (metabolism)
• Osteogenesis (drug effects)
• Osteoporosis (complications, drug therapy, metabolism)
• Randomized Controlled Trials as Topic
• Rats
• Stimulation, Chemical
• Vitamin D (administration & dosage, analogs & derivatives, pharmacology)